Wayne William Hancock, MD, PhD, FRCPA

faculty photo
Professor of Pathology and Laboratory Medicine
Department: Pathology and Laboratory Medicine
Graduate Group Affiliations

Contact information
916B Abramson Research Center
3615 Civic Center Blvd.
Philadelphia, PA 19104-4318
Office: (215) 590-8709
Fax: (215) 590-7384
Education:
M.B.B.S. (Medicine)
Monash University, Clayton, Victoria, Australia, 1977.
Ph.D. (Medicine)
Monash University, Clayton, Victoria, Australia, 1984.
F.R.C.P.A. (Pathology)
Royal College o fPathologists of Australasia, 1989.
Permanent link
 

Description of Research Expertise

Research Interests

Transplant immunobiology, inflammation and mechanisms of disease

Research Summary

New Co-Stimulation Molecules And Their Function In Vivo
The world is currently awash with costimulation molecules. Individual labs tout this or that molecule as being key to T cell activation under specific (often ludicrously specific) conditions, but none of these "insights" have yet led to actual therapeutic agents in clinical use. This reflects several factors. Drug companies make drugs and then try and find an application for them, ideally rheumatoid arthritis, multiple sclerosis, asthma or some other widespread disease involving long-term therapy, but certainly not any of the indications subject to the "too small a market (e.g. <$200 million dollars/year)" rule. Biologics are difficult and expensive to develop. Hence, the science underlying all the costimulation hype needs to examined critically if progress is to be achieved. Rather than adding more and more costimulation molecules to the list and thinking they are all equally important such that the Immunology Today-type diagrams in peoples' minds becomes more and more complicated, some reality testing is called for, and may thereby lead to new therapeutic approaches. Transplant models provide particularly advantageous systems to test the importance of such costimulation pathways using knockouts and blocking monoclonal antibodies and fusion proteins. We are currently investigating ICOS/B&RP-1; PD-1 and its ligands, PD-L1 and PD-L2; B7-H3; BTLA and B7-H4; and several TNF/TNF-R superfamily pathways, i.e. those molecules which constitute the "next wave" on which immunologic hopes, careers and dreams typically seem to be pinned upon but which in this case, as a bonus, may also be "true".

Chemokines/chemokine receptors in allograft rejection vs. tolerance
If all the world is a stage than an organ transplant is from an immunologic perspective a gothic masterpiece wherein every component of the immune system boils and pokes its way into the limelight at some point or another and the challenge is to make sense of it all. Chemokines are small molecular weight chemotactic cytokines which bind and signal via G protein-coupled seven-transmembrane receptors expressed by most cell types. Of special interest to immunologists are those chemokine receptors which mediate T cell recirculation as well as those which mediate attraction to sites of immune stimulation, such as an organ transplant. This field has its problems, not the least of which is its dreaded new nomenclature which has only served to decrease rather than improve communication. Suffice to say that despite there being over 45 chemokines and at least 18 chemokine receptors, with countless assertions of biologic redundancy and "promiscuous" binding (which sound interesting but isn't in this case), the development and testing of knockout mice and availability of neutralizing mAbs for use in wild-type controls has provided some sense of insight into how these pathways work in vivo. Of the various pathways involved in allograft responses, the most important seems to be CXCR3, which is expressed by NK cells and activated T cells, and has 3 ligands: IP-10, Mig and I-TAC. Blockade of CXCR3 has a particularly powerful effect in reducing host alloresponses. The second most important appears to be CCR5, whose ligands are many but include MIP-1a, MIP-1b and RANTES. We continue to investigate the importance of these and additional chemokine/chemokine receptor pathways in experimental and clinical studies.

Selected Publications

Levine MH, Wang Z, Wang Y, Bhatti T, McNeal S, Liu Y, Cheraghlou S, Han R, Wang L, Hancock WW. : Class-specific histone/protein deacetylase inhibition protects against renal ischemia reperfusion injury and fibrosis formation. American Journal of Transplantation 154, April 2015.

Arva NC, Russo PA, Erlichman J, Hancock WW, Haber BA, Bhatti TR. : The inflammatory phenotype of the fibrous plate is distinct from the liver and correlates with clinical outcome in biliary atresia. Pathology Research and Practice 211, March 2015.

Wang L, Liu Y, Han R, Beier UH, Bhatti TR, Akimova T, Greene MI, Hiebert SW, Hancock WW. : FOXP3+ regulatory T cell development and function require histone/protein deacetylase 3. Journal of Clinical Investigation 125, March 2015.

Quatromoni J, Singhal S, Bhojnagarwala P, Hancock WW, Albelda S, Eruslanov E. : An optimized disaggregation method for human lung tumors that preserves the phenotype and function of the immune cells. Journal of Leukocyte Biology 97, January 2015.

Akimova T, Levine MH, Beier UH, Hancock WW. : Standardization, evaluation and area-under-curve analysis of human and murine Treg suppressive function. Methods in Molecular Biology In press, 2015.

Beier UH, Angelin A, Akimova T, Wang L, Liu Y, Xiao H, Koike MA, Hancock SA, Bhatti TR, Han R, Jiao J, Veasey SC, Sims CA, Baur JA, Wallace DC, Hancock WW. : Essential role of mitochondrial energy metabolism in Foxp3+ T-regulatory cell function and allograft survival. FASEB Journal In press, 2015.

Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, Stephen TL, Ranganathan A, Deshpande C, Akimova T, Vachani A, Litzky L, Hancock WW, Conejo-Garcia JR, Feldman M, Albelda SM, Singhal S. : Inflammatory tumor-associated neutrophils in early stage human lung cancer. Journal of Clinical Investigation 124, 2014, 5466-5480 124, December 2014.

Liu Y, Wang L, Han R, Beier UH, Akimova T, Bhatti TR, Xiao H, Cole PA, Brindle PK, Hancock WW. : Two histone/protein acetyltransferases, CBP and p300, are indispensable for Foxp3+ T-regulatory cell development and function. Molecular and Cellular Biology 34: 3993-4007, November 2014.

Cheng F, Lienlaf M, Wang HW, Perez-Villarroel P, Lee C, Woan K, Rock-Klotz J, Sahakian E, Woods D, Pinilla-Ibarz J, Kalin J, Tao J, Hancock WW, Kozikowski A, Seto E, Villagra A, Sotomayor EM. : A novel role for histone deacetylase 6 (HDAC6) in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs. Journal of Immunology 193: 2850-2862, September 2014.

Xiao Y, Nagai Y, Deng G, Ohtani T, Zhu Z, Zhou Z, Zhang H, Ji MQ, Lough JW, Samanta A, Hancock WW, Greene MI.: Dynamic interactions between TIP60 and p300 regulate FOXP3 function through a structural switch defined by a single lysine on TIP60. Cell Reports 7: 1471-1480, July 2014.

back to top
Last updated: 03/28/2015
The Trustees of the University of Pennsylvania